Neurofibromatosis Type 2 (NF2) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2021 To 2032

Neurofibromatosis type 2 (NF2) is an autosomal-dominant tumor-prone disorder predisposed to nerve system tumors. Bilateral vestibular schwannoma (VS) is pathognomonic or the disease, whereas schwannoma at other locations, meningiomas, ependymomas, and early onset lenticular opacities are frequently associated with the phenotypes. Vestibular schwannoma-related symptoms were seen in most of the patients (55%), followed by ophthalmological symptoms/abnormalities (45%) and cutaneous features (38%). About 40% of all patients were monosymptomatic, 55% showed ≥2 symptoms at symptom onset, and ~5% were asymptomatic. Including polysymptomatic occurrence and symptomatic and asymptomatic findings, 62% of young patients exhibit ophthalmological abnormalities, followed by cutaneous findings (43%). Most people with NF2 develop symptoms in the late teen and early adult years, although about 10% of people develop symptoms during late childhood. The most common symptoms of NF2 include ringing in the ears (tinnitus), gradual hearing loss, and balance problems.

 

Neurofibromatosis type 2 (NF2) incidence ranges from 1 to 1.2 cases in 40,000 live birth Neurofibromatosis type 2 (NF2).

 

The competitive landscape of Neurofibromatosis Type 2 (NF2) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Neurofibromatosis Type 2 (NF2) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Neurofibromatosis Type 2 (NF2) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Neurofibromatosis Type 2 (NF2) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          REC-2282         Recursion Pharmaceuticals Inc. Phase 3

2          Icotinib  Betta Pharmaceuticals Co., Ltd. Phase 2

3          VT3989 Vivace Therapeutics, Inc            Phase 1

4          IK-930  Ikena Oncology Phase 1

5          Mirdametinib (PD-0325901)       SpringWorks Therapeutics, Inc.            Phase 2

6          Endostatin        Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd Phase 2

 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033